ArticleNature communications2017
MICU1 drives glycolysis and chemoresistance in ovarian cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 170 citations in OpenAlex.
- Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance.Journal of advanced research · 2026Review
- Spatial multi-omics guides ASCT2-targeted delivery of glycolysis inhibitor for cervical cancer suppression and chemoresistance reversal.Journal of advanced research · 2026Article
- Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer.Nature communications · 2026Article
- Lactate-Induced ZMYM2 K529 Lactylation Stabilizes ZMYM2 and Promotes Platinum Resistance in Ovarian Cancer.International journal of molecular sciences · 2026Article
- A systemic immunogenic reactor leveraging modifiedActa pharmaceutica Sinica. B · 2026Article
- Mitochondria-ER crosstalk via MAMS: Bridging cellular homeostasis and cancer progression.Apoptosis : an international journal on programmed cell death · 2026Review
- Novel strategies for mitigating hepatic ischemia-reperfusion injury: targeting MICU1 and calcium-glycolytic homeostasis with acteoside.International journal of biological sciences · 2026Article
- Glycolytic reprogramming in ovarian cancer: mechanisms, immune crosstalk, and therapeutic implications.Frontiers in immunology · 2026Review
- Subcellular Stress Markers in Epithelial Ovarian Cancer.International journal of molecular sciences · 2025Review
- NAT10 promotes glycolysis and cell stemness of ovarian cancer cells via ac4C acetylation of PGAM1 mRNA.Scientific reports · 2025Article
- EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025Review
- Role of metabolic reprogramming of cancer‑associated fibroblasts in tumor development and progression (Review).International journal of oncology · 2025Review
- Trichosanthin elicits antitumor activity via MICU3 mediated mitochondria calcium influx.Journal of advanced research · 2025Article
- Mitochondrial CaJournal of cellular physiology · 2025Review
- TMEM65 functions as the mitochondrial NaNature cell biology · 2025Article
- HRP2 regulating MICU1-mediated CaNeoplasia (New York, N.Y.) · 2025Article
- Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance.Journal of hematology & oncology · 2025Review
- Review
- Integration of scRNA-seq and bulk RNA-seq to reveal the association and potential molecular mechanisms of metabolic reprogramming regulated by lactylation and chemotherapy resistance in ovarian cancer.Frontiers in immunology · 2025Article
- Calcium signaling in mitochondrial intermembrane space.Biochemical Society transactions · 2024Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Prabir K ChakrabortyDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Soumyajit Banerjee MustafiDepartment of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Xunhao XiongDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Shailendra Kumar Dhar DwivediDepartment of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Vasyl NesinDepartment of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma 73104, USA.
Sounik SahaDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Min ZhangDepartment of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, USA.
Danny DhanasekaranDepartment of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma 73104, USA.
Muralidharan JayaramanDepartment of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma 73104, USA.ORCID 0000-0003-3274-877X
Robert MannelDepartment of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Kathleen MooreDepartment of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Scott McMeekinDepartment of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Da YangDepartment of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, USA.
Rosemary ZunaDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Kai DingCollege of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Leonidas TsiokasDepartment of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma 73104, USA.
Resham BhattacharyaDepartment of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Priyabrata MukherjeeDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
University of Oklahoma Health Sciences Center · USUniversity of Pittsburgh · US
Funding
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HANNAFON, BETHANY · 2012 to 2022
$21.3MMolecular Mechanism of Antiangiogenic Properties of Gold NanoparticleR01CA136494 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2009 to 2020
$2.9MCystathionine beta synthase (CBS) and angiogenesisR01HL120585 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2013 to 2017
$2.1MCalcium Regulation in OsteoclastsR01AR064211 · NIAMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HUMPHREY, MARY BETH, TSIOKAS, LEONIDAS · 2013 to 2017
$2.1MBmi-1, a potential therapeutic target in ovarian cancerR01CA157481 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM · 2012 to 2016
$1.6MExploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6MRole of miR-195 in Chemo-Resistant Ovarian CancerR21CA280507 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DWIVEDI, SHAILENDRA KUMAR DHAR · 2023 to 2023
$169kNCI NIH HHS R01 CA136494NCI NIH HHS R01 CA157481NCI NIH HHS R01 CA260449NCI NIH HHS R21 CA280507NHLBI NIH HHS R01 HL120585NIAMS NIH HHS R01 AR064211NIGMS NIH HHS P20 GM103639
Abstract
Cancer cells actively promote aerobic glycolysis to sustain their metabolic requirements through mechanisms not always clear. Here, we demonstrate that the gatekeeper of mitochondrial Ca
Indexed as
Drug Resistance, NeoplasmGlycolysisAnimalsAntineoplastic AgentsApoptosisCalciumCalcium-Binding ProteinsCation Transport ProteinsCell Line, TumorCisplatinFemaleHumansMice, NudeMicroarray AnalysisMitochondrial Membrane Transport ProteinsOvarian NeoplasmsAntineoplastic AgentsCalciumCalcium-Binding ProteinsCation Transport ProteinsCisplatinMICU1 protein, humanMitochondrial Membrane Transport ProteinsPyruvate Dehydrogenase Complex
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.